MAR-AZITHROMYCIN TABLET
Država: Kanada
Jezik: engleski
Izvor: Health Canada
Svojstava lijeka
(SPC)
12-08-2020
Neki dokumenti za ovaj proizvod trenutno nisu dostupni, možete poslati zahtjev u našu korisničku službu i mi ćemo vas obavijestiti čim ih budemo mogli dobiti.
Pošalji zahtjev.
Pošalji zahtjev.
Aktivni sastojci:
AZITHROMYCIN (AZITHROMYCIN DIHYDRATE)
Dostupno od:
MARCAN PHARMACEUTICALS INC
ATC koda:
J01FA10
INN (International ime):
AZITHROMYCIN
Doziranje:
600MG
Farmaceutski oblik:
TABLET
Sastav:
AZITHROMYCIN (AZITHROMYCIN DIHYDRATE) 600MG
Administracija rute:
ORAL
Jedinice u paketu:
30/100/500
Tip recepta:
Prescription
Područje terapije:
OTHER MACROLIDES
Proizvod sažetak:
Active ingredient group (AIG) number: 0126072005; AHFS:
Status autorizacije:
APPROVED
Datum autorizacije:
2016-09-08
Svojstava lijeka
Page 1 of 63
PRODUCT MONOGRAPH
Pr
MAR-AZITHROMYCIN
Azithromycin Dihydrate Tablets
250 mg and 600 mg Azithromycin (supplied as azithromycin dihydrate),
manufacturer’s standard
Antibacterial Agent
Marcan Pharmaceuticals Inc. Date of Revision:
2 Gurdwara Road, Suite #112 August 12, 2020
Ottawa, Ontario
Canada, K2E 1A2
Control Number: 241406
Page 2 of 63
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................
8
DRUG INTERACTIONS
.......................................................................................................................
14
DOSAGE AND ADMINISTRATION
...................................................................................................
19
OVERDOSAGE
......................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................
20
STORAGE AND STABILITY
...............................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................... 23
PART II: SCIENTIFIC INFORMATION
..................................................................
Pročitajte cijeli dokument
